An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes

Journal of the American Board of Family Medicine

Volumn 26, Issue 2, 2013, Pages 203-210

  Painter, Nathan A ^a   Morello, Candis M ^a,b   Singh, Renu F ^a   McBane, Sarah E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Chronic disease; Diabetes mellitus; Drugs; Evidence based medicine; Pharmacology; Pharmacotherapy

Indexed keywords

EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; HYDROCORTISONE; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; WARFARIN;

BLEEDING; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DIARRHEA; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; ERYTHEMA; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PAIN; STOMACH EMPTYING; WEIGHT CHANGE; WEIGHT REDUCTION;

DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PANCREATITIS; PATIENT EDUCATION AS TOPIC; PEPTIDES; VENOMS;

EID: 84875872427     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2013.02.120174     Document Type: Review

References (27)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed January 14, 2013.
2. Nichols GA, Kimes TM, Harp JB, Kou TD. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care 2012;35:495-7.
3. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012; 35(Suppl 1):S11-63.
4. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
5. Drucker DJ, Nauck, MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;268:1696-705. (Pubitemid 46048557)
6. Amylin Pharmaceuticals. Highlights of prescribing information: Bydureon. January 2012. Available from: http://documents.bydureon.com/Bydureon-PI.pdf. Accessed January 14, 2013.
7. Amylin Pharmaceuticals. Highlights of prescribing information: Byetta. December 2011. Available from: http://documents.byetta.com/Byetta-PI.pdf. Accessed January 14, 2013.
8. Novo Nordisk. Highlights of prescribing information: Victoza. April 2012. Available from: http://www.novo-pi.com/victoza.pdf. Accessed January 14, 2013.
9. Merck. Highlights of prescribing information: Januvia. April 2012. Available from: http://www.merck.com/product/usa/pi-circulars/j/januvia/januvia- pi.pdf. Accessed January 14, 2013.
10. Bristol-Myers Squibb. Highlights of prescribing information: Onglyza. December 2011. Available from: http://packageinserts.bms.com/pi/pi-onglyza.pdf. Accessed January 14, 2013.
11. Boehringer-Ingelheim International GmBH. Highlights of prescribing information: Tradjenta. September 2012. Available from: http://hcp.tradjenta. com/prescribing-information. Accessed January 14, 2013.
12. Rich, R CPhT. Personal communication. Outpatient Pharmacy Services. University of California, San Diego Medical Center. Cost provided October 9, 2012.
13. Alkermes Pharmaceuticals. Fact sheet: Medisorb Microspheres Technology. January 2009. Available from: http://www.biotechinvest.net/uploads/Medisorb.pdf. Accessed January 14, 2013.
14. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13:1145-54.
15. Drucker DJ, Buse JB, Taylor K, et al; DURA TION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50.
16. Blevins T, Pullman J, Malloy J, et al. DURA TION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10.
17. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93. (Pubitemid 46871159)
18. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43.
19. Buse JB, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6):a randomised, open-label study. Diabetologia 2011; 54(Suppl 1):A75.
20. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptan or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet 2010;376:431-9.
21. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252-8.
22. Fineman MS, Mace KF, Diamant M., et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012;4:546-54.
23. Amylin Pharmaceuticals. Medication guide: Bydureon. January 2012. Available from: http://documents.bydureon.com/Bydureon-Medication-Guide.pdf. Accessed January 14, 2013.
24. Amylin Pharmaceuticals, Inc. Bydureon [homepage]. Available from: http://www.bydureon.com. January 14, 2013.
25. Lorenzi G, Schreiner B, Osther J, Boardman M. Application of adult-learning principles to patient instructions: a usability study for an exenatide once-weekly injection device. Clin Diabetes 2010; 28:157-62.
26. Buse JB, Drucker DJ, Taylor KL, et al; DURA TION-1 Study Group. DURATION-1: exenatide once weekly produce sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33: 1255-61.
27. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.